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Abstract
Mutation of the tumor suppressor p53 plays a major role in human carcinogenesis. Here we describe gene-targeted porcine
mesenchymal stem cells (MSCs) and live pigs carrying a latent TP53R167H mutant allele, orthologous to oncogenic human
mutant TP53R175H and mouse Trp53R172H, that can be activated by Cre recombination. MSCs carrying the latent TP53R167H
mutant allele were analyzed in vitro. Homozygous cells were p53 deficient, and on continued culture exhibited more rapid
proliferation, anchorage independent growth, and resistance to the apoptosis-inducing chemotherapeutic drug
doxorubicin, all characteristic of cellular transformation. Cre mediated recombination activated the latent TP53R167H allele
as predicted, and in homozygous cells expressed mutant p53-R167H protein at a level ten-fold greater than wild-type MSCs,
consistent with the elevated levels found in human cancer cells. Gene targeted MSCs were used for nuclear transfer and
fifteen viable piglets were produced carrying the latent TP53R167H mutant allele in heterozygous form. These animals will
allow study of p53 deficiency and expression of mutant p53-R167H to model human germline, or spontaneous somatic p53
mutation. This work represents the first inactivation and mutation of the gatekeeper tumor suppressor gene TP53 in a non-
rodent mammal.
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Introduction
Cancers are the fourth most common cause of death worldwide
and predicted to increase with longer human life expectancy.
Current statistics indicate that more than 40% of people alive
today will be diagnosed with some form of cancer during their
lifetime [1]. Years of basic research and advances in cancer
genetics and medicinal chemistry have provided a wealth of
knowledge that promise to revolutionize cancer detection and
treatment. The challenge now is to translate these accomplish-
ments into clinical benefit for patients in a safe and efficient
manner.
The transcription factor p53 is a vital tumor suppressor that
inhibits cell cycle progression following DNA damage and
promotes senescence or apoptosis in response to stress. Modifica-
tion of p53 function occurs in the majority of human cancers [2],
and germline mutations in TP53 are responsible for Li Fraumeni
multiple cancer syndrome [3]. The location, type and frequency of
TP53 somatic mutations have been surveyed across a wide range
of human cancers, 86% lie between codons 125 and 300, broadly
corresponding to the DNA binding region [4]. Certain mutations
exhibit a dominant negative effect and may impart gain-of-
function oncogenic properties [5]. The R175H mutation is of this
type. Mutant p53-R175H inhibits wild-type p53 interaction with
promoter elements [6], advances angiogenesis [7], and promotes
epithelial mesenchymal transition [8] important in metastasis and
tumor invasion. A survey of somatic p53 mutations compiled by
the International Agency for Research on Cancer reveals R175H
as the most frequent missense mutation in many sporadic human
cancers [9].
Many Trp53 modifications have been generated in mice,
including knockout and inducible oncogenic activation mutations
[10]. Mice provide powerful tools for cancer genetics, identifica-
tion of possible therapeutic targets and proof-of-principle exper-
iments. But mice are not men, their small size and short lifespan
restrict the types of study that can be carried out. There is a need
for genetically defined models of cancer and cancer predisposition
in other species. Larger, longer-lived animals offer the advantage
that disease initiation, progression and response to treatment can
be closely monitored in real time under conditions similar to
human patients. Many important parameters can be followed in
longitudinal studies, such as early tumor markers, the presence of
circulating tumor cells, tumor progression and remission, response
or failure of drug therapy, and the acquisition of drug resistance by
cancer cells.
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Our aim is to facilitate preclinical research and the evaluation of
new diagnostic and therapeutic procedures in human oncology.
Here we describe a gene-targeted pig line carrying a latent
TP53R167H mutant allele orthologous to human TP53R175H that
can be activated by Cre recombination to model Li Fraumeni
syndrome and oncogenic mutant p53 found in sporadic human
cancers.
Results
We engineered a latent oncogenic mutant porcine TP53 gene
by insertion of a floxed transcriptional termination signal (LSL
cassette) in the first intron and a point mutation encoding the
oncogenic activation mutation R167H (equivalent to human
R175H and mouse R172H) in exon 5. The intact allele,
designated TP53LSLR167H, is predicted to lack TP53 expression.
Cre recombinase-mediated removal of the LSL cassette generates
the allele designated TP53LR167H, which is predicted to express
mutant p53-R167H mRNA and protein.
Porcine TP53 gene targeting
Mesenchymal stem cell (MSC) isolates were prepared from the
bone marrow of Landrace/Pietrain cross breed pigs, or adipose
tissue of Landrace male pigs. Cell isolates capable of differentiation
into osteogenic, adipogenic and chondrogenic lineages were used.
MSCs were transfected separately with P53BSR or P53NEO
vectors. These vectors differ only in the drug selectable marker (bsr
or neo), see Figure 1A. Both employ a promoter trap strategy to
enrich targeted cell clones and include the fluorescent mCherry
gene as a visible counter-selectable marker to identify random
integrants.
Putative gene targeted cell clones were identified by lack of
mCherry fluorescence and PCR amplification of a 3.3 kb DNA
fragment from the LSL cassette across the shorter arm of
homology to a point outside the targeting vector, see Figure 1A.
One of eight P53NEO transfectants and seven of 78 P53BSR
transfectants were identified as targeted, an overall targeting
efficiency of 9.3%. Representative screening results are shown in
Figure S1. The presence of the G to A mutation (encoding
R167H) in exon 5 was tested by PCR amplification and sequence
analysis across the mutation site. Six cell clones with both G and A
nucleotides at the mutation site, indicating heterozygosity, were
identified. The P53NEO targeted cell clone (neo14) showed only
the A nucleotide, see Figure 1B, indicating either homo- or
hemizygosity. Subsequent analysis confirmed that this clone was
TP53LSLR167H/LSLR167H homozygous, as described later. Sequence
analysis also indicated loss of 223 bp intron sequence adjacent to
the LSL cassette in this clone in both alleles.
TP53 gene targeted pigs
One nuclear transfer experiment was carried out with the single
TP53LSLR167H/LSLR167H bone marrow derived cell clone neo14.
Embryos were transferred to one recipient and one pregnancy
established. Two fully developed male piglets with normal birth
weights (1.2 and 1.7 kg) were born, however these exhibited
macroglossia causing asphyxia and death at birth. This abnor-
mality has previously been noted after nuclear transfer in pigs [11]
and other mammalian species [12], and is understood to be a
consequence of defective epigenetic reprogramming. It is almost
certainly related to the cell type used and not the TP53 mutation,
because animals derived from the same bone marrow MSC
preparation for another targeting project showed a similar defect.
No further nuclear transfer experiments were carried out with
these cells.
Two sets of nuclear transfer experiments were carried out with
the heterozygous TP53LSLR167H/+ adipose derived cell clones bs29
and bs33. Clones bs29 and bs33 were chosen because the original
colonies were well separated and unequivocally free of mCherry
fluorescent cells. They were pooled for nuclear transfer to increase
the chance of including a competent donor. Reconstructed
embryos were transferred to six recipients, four pregnancies
established and a total of 15 piglets born, all male. In contrast to
nuclear transfer with bone marrow cells, all 15 piglets were free of
any apparent abnormality and remain so at the time of writing.
Piglets were first analyzed by PCR to detect targeted insertion of
the LSL cassette and presence of the R167H mutation. Both
animals from clone neo14 were confirmed as TP53LSLR167H/
LSLR167H and all 15 animals from clones bs29/bs33 as
TP53LSLR167H/+. Figure 1C shows Southern blot analysis of cell
clones neo14 and bs29 and representative nuclear transfer derived
piglets. A diagnostic ScaI fragment was used to indicate insertion of
the LSL cassette (see Figure 1A). Fragments indicative of wild-type
and targeted TP53 alleles were detected in TP53LSLR167H/+
animals, while neo14 derived TP53LSLR167H/LSLR167H piglets did
not show the wild-type fragment. The internal probe used
(Figure 1A) would also have revealed any random integrations of
the targeting vector, none were detected.
A series of experiments were carried out to investigate the
function and phenotype of the targeted TP53 allele in vitro, in
preparation for in vivo characterization of the phenotype in whole
animals.
Activation of targeted TP53 allele by Cre transduction
The floxed transcription termination cassette in intron 1 was
predicted to block expression of the TP53LSLR167H allele, and the
block released by Cre-mediated excision. We examined the effects
of Cre protein transduction into targeted cell clones bs29 and
neo14. As shown in Figure 2A, non-targeted MSCs amplified only
the wild-type TP53 fragment. Heterozygous TP53LSLR167H/+ cell
clone bs29 amplified wild-type and non-excised LSL (bsr)
fragments before Cre transduction, and wild-type and excised
loxP remnant fragments after transduction. TP53LSLR167H/
LSLR167H cell clone neo14 amplified only the non-excised LSL
(neo) fragment before Cre transduction, and only the excised loxP
remnant fragment after transduction.
Cre recombination was also used to confirm that clone neo14
was TP53LSLR167H/LSLR167H homozygous, rather than
TP53LSLR167H/2 hemizygous. Neo14 cells were subjected to Cre
transduction, individual G418 resistant subclones selected and
isolated and their TP53 genotype analyzed. Two subclones
showed both a non-excised LSL (neo) and a loxP remnant
fragment, indicating that the parental clone neo14 possessed two
gene-targeted TP53 alleles. Figure 2A shows TP53LSLR167H/LR167H
subclone neo14/1.2.
The G to A substitution in codon 167 results in loss of a HaeII
restriction enzyme recognition site, see Figure 1B. We used RT-PCR
amplification of a 1.313 kb RT-PCR product from exon 1 to exon 11
to detect p53 mRNA expression and HaeII digestion to distinguish
mutant and wild-type p53. Figure 2B showsHaeIIRT-PCR analysis of
TP53LSLR167H/+ cell clone bs29 and TP53LSLR167H/LSLR167H cell clone
neo14 before and after Cre recombination, and also the partially
recombined TP53LSLR167H/LR167H subclone neo14/1.2. The charac-
teristic HaeII fragments are indicated. Results clearly indicate that the
TP53LSLR167H allele lacks p53 mRNA expression, and is thus a null
allele. Cre mediated excision of the LSL cassette activates mutant p53-
R167H mRNA expression. This demonstrates tight blockade and
release of the targeted allele.
Porcine p53 Knockout and Mutation
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Elevated levels of mutant p53-R167H protein in porcine
MSCs
Wild-type p53 protein is maintained at low level in normal cells,
mainly by MDM2-mediated ubiquitination and degradation [13].
Some mutant p53 proteins, such as human R175H, lack the ability
to transactivate MDM2 and thus accumulate in cancer cells [14].
We assessed whether the porcine R167H mutation has a similar
effect. Figure 3A shows Western blot analysis of wild-type MSCs
and cell clone neo14 before and after Cre transduction. p53
protein expression is evident in wild-type MSCs, but absent in
neo14. Following Cre transduction, neo14 cells express abundant
p53 protein. Gel density analysis of three Western blots showed
approximately ten-fold more mutant p53-R167H in induced
neo14 cells than wild-type p53 in untargeted MSCs; data were
normalized to the GAPDH signal. The ,46 kDa size we observed
for porcine p53 is consistent with that previously reported [15].
These data indicate that, like human R175H and mouse R172H,
the porcine R167H mutation causes p53 accumulation.
Figure 1. Porcine TP53 gene targeting. A) Porcine TP53 gene targeting scheme. Top. Porcine TP53 gene. Exon numbers are indicated, coding and
non-coding regions are marked as black and grey boxes. Below. Structure of P53BSR and P53NEO targeting vectors. The transcription termination
cassette and its insertion site in intron 1 is shown, the G to A substitution mutation in exon 5 is indicated by an asterisk. Detailed descriptions of each
vector are provided in materials and methods. PCR and RT-PCR primers used to identify targeted cell clones, detect mRNAs, detect presence and loss
of the transcriptional termination cassette, and to amplify the mutated region in exon 5 are indicated. ScaI restriction sites and the hybridization
probe used for Southern analysis are also shown. B) Sequence analysis across codon 167. Representative chromatograms of exon 5 region including
the engineered R167H mutation showing wild-type, heterozygous and homozygous mutation sequences detected in targeted cell clones. The HaeII
restriction enzyme site used to distinguish mutant from wild-type RT-PCR fragments is also shown. C) Southern blot analysis of cell clones and piglets.
A diagnostic ScaI fragment was used to assess targeted integration at the TP53 locus. Predicted sizes for TP53 alleles are: wild-type TP53 3.16 kb,
TP53LSLR167H (bsr) 4.5 kb, TP53LSLR167H (neo) 4.67 kb. ScaI digested genomic DNA from targeted cell clones and nuclear transfer derived piglets are as
indicated.
doi:10.1371/journal.pone.0043323.g001
Porcine p53 Knockout and Mutation
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p53 deficiency results in transformation of porcine MSCs
in vitro
Inactivation of p53 in mouse MSCs results in cell transforma-
tion [16]. Cell clone neo14 provided an opportunity to investigate
p53 deficiency in porcine MSCs. Most porcine primary cells can
only be maintained for a short time after genetic manipulation and
single cell cloning because, like most untransformed primary cells,
they undergo replicative senescence. This was not the case with
the TP53LSLR167H/LSLR167H cell clone neo14. After a short time in
culture (2 weeks after single cell cloning), neo14 cells exhibited a
noticeable change in growth characteristics. The rate of prolifer-
ation increased compared to wild-type MSCs and TP53LSLR167H/+
cell clones, with the time required for cell doubling decreasing
from ,72 h to ,24 h. Cell morphology also changed from
fibroblast-like to a smaller, round shape. Unlike the parental
MSCs, this cell clone could sustain multiple rounds of subcloning,
and has been passaged at 1:10 dilution more than 60 times with no
evidence of replicative senescence.
The ability of individual cells to form colonies in soft agar was
investigated as a simple, standard test of cellular transformation.
Wild-type MSCs, TP53LSLR167H/LSLR167H neo14 p53 deficient
cells, and Cre transduced TP53LR167H/LR167H neo14 cells were
compared. Four weeks after plating 16103 cells no colonies greater
than 50 mm diameter were obtained from wild-type MSCs. Neo14
produced an average of 70 (+/27) and Cre-transduced neo14 cells
an average of 100 (+/222) colonies, based on three replicate
experiments. Figure 3C illustrates typical colony appearance.
p53 deficiency confers chemoresistance in vitro
p53 deficiency or oncogenic p53 mutations are known to confer
increased resistance to the chemotherapeutic drugs such as
cisplatin and doxorubicin in mouse and human cells [17,18].
We used a doxorubicin assay to investigate p53-mediated
apoptosis. As Figure 3B shows, wild-type porcine MSCs were
completely killed by doxorubicin. The p53 deficient cell clone
neo14 showed resistance, and this was not affected by inducing
Figure 2. Blockade and release of the TP53LSLR167H allele. A) Cre recombination removes the LSL cassette from the TP53LSLR167H allele. Gel
analysis of PCR amplification products across the site of LSL insertion in porcine TP53 intron 1 in: wild-type MSCs, TP53LSLR167H/+ cell clone bs29 before
and after Cre transduction; the TP53LSLR167H/LSLR167H cell clone neo14, the partially Cre-recombined cell subclone neo14/1.2 (TP53LSLR167H/LR167H); and
cell clone neo14 after Cre transduction (TP53LR167H/LR167H) as indicated. Predicted fragment sizes are: wild-type TP53 198 bp, non-excised LSL (bsr)
1.536 kb, non-excised LSL (neo) 1.929 kb. Cre-mediated LSL excision was predicted to leave a 34 bp loxP site and a 22 bp vector remnant that lies
outside the floxed region; thus a 254 bp amplified fragment. B) Cre recombination activates mutant p53-R167H mRNA expression. Gel analysis of RT-
PCR amplification products of mRNAs (exon 1 to exon 11) expressed from wild-type and activated mutant TP53 alleles. RT-PCR products are
distinguished by digestion with HaeII. The G to A mutation in codon 167 removes a HaeII site present in wild-type p53, see Figure 1B. Lanes show
wild-type MSCs, TP53LSLR167H/+ cell clone bs29 before and after Cre transduction; TP53LSLR167H/LSLR167H cell clone neo14, the partially Cre-recombined
cell subclone neo14/1.2 (TP53LSLR167H/LR167H); and cell clone neo14 after Cre transduction (TP53LR167H/LR167H) as indicated. Predicted sizes for HaeII
digested amplified RT-PCR fragments are: wild type TP53 698 bp, 310 bp, 287 bp and 18 bp; Cre-recombined TP53LR167H allele 985 bp, 310 bp and
18 bp.
doi:10.1371/journal.pone.0043323.g002
Porcine p53 Knockout and Mutation
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mutant p53-R167H expression, as shown by the doxorubicin
resistance of Cre-transduced neo14 cells.
These in vitro data show that the TP53LSLR167H allele is tightly
repressed and can readily be activated by Cre recombination. p53
deficiency results in phenotypic changes in porcine primary cells
consistent with oncogenic transformation. Expression of mutant
p53-R167H results in overabundance of the protein and no
reversal of the phenotypic changes, indicating that mutant p53-
R167H lacks normal p53 function.
Discussion
With a few exceptions, cancer mortality statistics have shown
little improvement over the past twenty years and there is a clear
need to translate novel diagnostic and therapeutic strategies into
the clinic. The need to move beyond the current heavy reliance on
rodent models for drug and medical device development is
increasingly recognized by preclinical researchers and pharma-
ceutical companies. The pig is very suitable for translational
research [19,20] because of its physiological and pharmacological
similarities to humans. Here we describe an important new
resource for preclinical oncology, pigs with a latent oncogenic
mutant p53-R167H (orthologous to human R175H and mouse
R172H) that can be activated by Cre recombinase, or in its
unrecombined form be used as a TP53 null allele. TP53 is mutated
or silenced in the majority of human cancers and mutations in
TP53 play a central role in evading growth suppression in tumor
progression and metastasis. In some cases, for example in Li-
Fraumeni syndrome, inactivation or expression of oncogenic p53
can be the initiating factor of tumorigenesis [3]. The p53 pathway
is therefore an attractive candidate for anti-cancer therapy [21].
Our data show that TP53 targeting in MSCs was efficient.
Using promoter trap vectors, 9.3% of primary cell clones analyzed
showed correct gene targeting, 86% of clones found to contain the
LSL cassette had also incorporated the R167H mutation.
Moreover one clone showed the targeted LSL insertion and
R167H mutation in both alleles. While the bone marrow MSC
isolate used to derive this clone was not fully competent for the
production of viable piglets, this cell clone provided valuable data
in vitro, demonstrating that p53 inactivation and mutation in
porcine primary MSCs results in a transformed phenotype and
resistance to chemotherapeutic drug-induced apoptosis.
This suggests that p53 inactivation may also cause tumor
initiation in vivo in homozygous knockout pigs. We expect such
Figure 3. Porcine p53 deficiency and mutant p53-R167H expression cause phenotypic changes in vitro. A) Cre recombination activates
abundant mutant p53-R167H protein expression. The Western blot shows detection of p53 and GAPDH in wild-type MSCS and the cell clone neo14
before (TP53LSLR167H/LSLR167H) and after Cre transduction (TP53LR167H/LR167H) as indicated. Protein size markers are shown. B) p53 deficiency confers
resistance to doxorubicin, this is not reversed by mutant p53-R167H expression. Top, wild-type porcine MSCs grown for 14 days untreated and after
treatment with doxorubicin, as indicated. Bottom, cell clone neo14 before (TP53LSLR167H/LSLR167H) and after Cre transduction (TP53LR167H/LR167H) grown
for 14 days after treatment with doxorubicin. Cells are stained with crystal violet. C) Anchorage independent growth of p53 deficient and mutant p53-
R167H expressing cells. Representative colonies after 4 weeks growth in soft agar. Wild-type MSCs, cell clone neo14 before (TP53LSLR167H/LSLR167H) and
after Cre transduction (TP53LR167H/LR167H) as indicated. Scale bar is 200 mm.
doi:10.1371/journal.pone.0043323.g003
Porcine p53 Knockout and Mutation
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animals to be viable, as shown for mice [22] and rats [23].
Production of nuclear transfer pigs from heterozygous targeted
cells (TP53LSLR167H/+) derived from adipose MSCs was very
efficient, with four of six recipient sows becoming pregnant and 15
healthy piglets obtained.
As yet the TP53LSLR167H/+ piglets show no signs of abnormal-
ities, but are being continuously monitored because TP53
hemizygous humans, mice and rats show increased rates of
tumorigenesis [23–25]. Significant phenotype differences have
been observed between species [23] [26], and the new porcine p53
animal models will enable interspecies comparison.
Conditional gene activation is a well established part of cancer
modeling in mice [27,28], but has not yet been extended to large
animals. We have demonstrated Cre activation of the latent
TP53LSLR167H allele and provided the first evidence that porcine
R167H mutation is functionally equivalent to orthologous
mutations in human and mouse cancer cells. We are thus
confident that in vivo activation of the R167H mutation will
result in a similar dominant negative effect in the whole animal.
Combining the inducible TP53 mutant allele with Cre expression
systems will provide temporal and tissue specific control over the
activation of mutant oncogenic p53 in vivo to mimic somatic
mutations responsible for human tumor formation.
Predictive preclinical animal trials are vital for cancer research
and the efficient transfer of new diagnostic and treatment
procedures into the clinic. The need for animal models at human
scale to bridge the gap between rodent models and human patients
is increasingly recognized. We are thus engaged in an integrated
program of targeted mutation of key tumor suppressor and proto-
oncogenes to provide a series of genetically-defined porcine models
of human cancers and cancer predispositions. We recently
reported pigs carrying gene-targeted mutations in the adenomatous
polyposis coli (APC) gene to model predisposition to colorectal cancer
[29]. The TP53 mutant pig line we describe here is a central
component in this campaign. As with rodents, precisely engineered
mutations can be brought into combination to model a variety of
human cancers. We are confident that the pigs described here will
provide powerful new resources for preclinical oncology and basic
cancer research.
Materials and Methods
Animal experiments were approved by the Government of
Upper Bavaria (permit number 55.2-1-54-2532-34-09) and
performed according to the German Animal Welfare Act and
European Union Normative for Care and Use of Experimental
Animals. Chemicals were obtained from Sigma-Aldrich Chemie
GmbH, cell culture media and supplements from PAA Labora-
tories GmbH unless otherwise specified.
Porcine TP53 gene targeting constructs
A porcine BAC clone (GenBank: AC127472.4) was used to
generate two gene-targeting vectors P53BSR and P53NEO. These
differed only in the drug selectable marker gene, see Figure 1A.
Each comprised: a 196 bp dual SV40 nuclear localization
sequence to facilitate nuclear entry of vector DNA (Dean et al.
1999); a 2.920 kb CAGGS promoter-mCherry cassette (in reverse
orientation) as a fluorescent counter-selectable marker; a 1.213 kb
59 short arm of homology corresponding to a region of TP53
intron 1 from a point 1.447 kb 59 of exon 2 to a PmlI restriction
enzyme site 234 bp 59 of exon 2; a floxed transcriptional
termination cassette (LSL); and a 10.96 kb region extending from
the PmlI site in intron 1 to a point 5.957 kb 39 of exon 11 that
includes a G to A substitution in exon 5 changing arginine to
histidine in codon 167 (R167H). The 1.3 kb LSL cassette of vector
P53BSR comprised: a loxP site; adenoviral splice acceptor;
promoterless blasticidin resistance gene (bsr); three poly-adenyla-
tion signals derived from SV40, bovine growth hormone and
cytomegalovirus; and a second loxP site. The 1.7 kb LSL cassette
of vector P53NEO was the same, but contained a promoterless
neomycin resistance gene (neo).
Generation of gene targeted porcine mesenchymal stem
cell (MSC) clones
MSCs were isolated by standard methods from leg bones or
subcutaneous fat of 6 to 7 month old male Landrace/Pietrain or
Landrace pigs. MSCs were cultured in advanced Dulbecco’s
modified Eagle medium (DMEM) (Gibco), 2 mM GlutaMAX, 16
non-essential amino acids, 10% fetal calf serum (FCS gold, lot
no. A15109-2859), 5 ng/ml FGF-2 (PromoKine) at 37uC, 5%
CO2 and passaged using Accutase. Samples of 1610
6 MSCs were
electroporated with 10 mg linearized targeting vector DNA and
selected with either 8 mg/ml blasticidin (Invivogen), or 600 mg/ml
G418. Colonies were examined by fluorescence microscopy to
visually identify and exclude those that expressed the mCherry
counter-selectable marker. Individual stable transfected cell clones
were isolated, samples of each clone cryopreserved at an early
stage and replicate samples cultured further for DNA, RNA and
protein analyses.
PCR and RT-PCR analysis of targeted MSC clones
Cell clones carrying the LSL cassette were identified using
primer targF (59 CCAGGGAGTCCATCTAAAAGTG 39), which
hybridizes to a point in intron 1 outside the targeting vector, and
primer targSAR (59 GAAAGACCGCGAAGAGTTTG 39), which
hybridizes to the LSL splice acceptor. PCR was carried out with
GoTaq polymerase (Promega). Thermal cycling parameters were:
5 min, 95uC; then 40 cycles of: 30 sec, 95uC; 30 sec, 59uC;
3:30 min, 72uC; followed by 5 min, 72uC. The diagnostic
amplified product was 3.308 kb.
The wild-type TP53 allele was amplified using primer targF
(sequence above) and primer int1R (59 TTCCACCAGTGAATC-
CACAA 39). Thermal cycling parameters were as above. The
diagnostic amplified product was 3.16 kb.
The presence of the G to A substitution in exon 5 was detected
by PCR amplification across the mutation site using primers mutF
(59 GTACTCCCCTGCCCTCAATA 39) and mutR (59
GGGGTAACCCATCTGCTCTA 39) followed by DNA se-
quence analysis. PCR was carried out with GoTaq polymerase.
Thermal cycling parameters were: 5 min, 95uC; then 35 cycles of:
30 sec, 95uC; 30 sec, 59uC; 30 sec, 72uC; followed by 5 min,
72uC.
Cre-mediated excision of the LSL cassette was detected by PCR
across the LSL insertion site using primers int1F (59 TGAG-
GAATTTGTATGCCAAGG 39) and int1R (sequence above)
with GoTaq polymerase. Thermal cycling parameters were:
5 min, 95uC; then 30 cycles of: 30 sec, 95uC; 30 sec, 58uC;
1:30 min, 72uC; followed by 5 min, 72uC.
mRNAs expressed from wild type TP53 and the Cre-
recombined TP53LR167H allele were detected by RT-PCR
amplification of a 1.313 kb fragment from exon 1 to exon 11 by
two step RT-PCR with Superscript III RT according to the
manufacturer’s instructions, using primers ex1F (59 GCAGG-
TAGCTGCTGGTCTC 39 ) and ex11R (59 AGGGACTT-
CAAAAGGGGATG 39) with GoTaq polymerase. Thermal
cycling parameters were: 3 min, 95uC; then 35 cycles of: 30 sec,
95uC; 30 sec, 58uC; 1:30 min, 72uC; followed by 3 min, 72uC.
Wild-type p53 and mutant p53-R167H RT-PCR products
Porcine p53 Knockout and Mutation
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containing the G to A substitution mutation were distinguished by
HaeII (NEB) digestion.
Somatic cell nuclear transfer
Nuclear transfer and embryo transfer were performed as
previously described [30]. Between 80–120 reconstructed embryos
were transferred to each recipient sow.
Southern blot analysis
ScaI (NEB) digested genomic DNA from cell clones or piglet ear
tip samples was electrophoresed, membrane bound, hybridized
and probe detected with anti-digoxigenin antibody Fab fragments
conjugated with alkaline phosphatase (Roche) by standard
methods. The 517 bp TP53 hybridization probe was generated
using primers probeF (59 GCAATGGAGGAGTCGCAGT 39)
and probeR (59 CTGCCAGGGTAGGTCTTCTG 39) incorpo-
rating alkali labile digoxigenin-11-dUTP (Roche). Thermal cycling
parameters were: 2 min, 95uC; then 35 cycles of: 30 sec, 95uC;
30 sec, 62uC; 40 sec, 72uC; followed by 8 min, 72uC. The location
of the hybridization probe is indicated in Figure 1A.
Cre transduction
Cre protein was produced in vitro with the vector pTriEx-
HTNC (Addgene plasmid 13763) according to the method
described by Peitz et al. [31] and Mu¨nst et al. [32]. Samples of
46104 cells in a 12 well dish were cultured with 5 mM purified Cre
recombinase in culture medium with reduced (0.5%) serum for
8 hours. Medium was replaced with standard medium and culture
continued.
Western blotting
Cultured cells were dissociated mechanically in 50 mM
HEPES, 150 mM NaCl, 1 mM EDTA, 0.5% IGEPAL CA-630,
10% glycerol, pH 7.9, containing 16 phosphatase inhibitor and
16 complete mini protease inhibitor (Roche). Protein was
quantified using advanced protein assay reagent (Cytoskeleton
Inc.). 40 mg total protein was loaded in each lane and separated by
15% SDS-PAGE. Blotting and detection of porcine p53 and
GAPDH was carried out as previously described [33]. Band
densities were quantified using the image analysis tool ImageJ
(http://rsb.info.nih.gov/ij/).
Soft agar growth assay
To investigate anchorage-independent growth, samples of
16103 cells were seeded on 6 well dishes into a layer of 0.4%
Noble agar in culture medium (DMEM, 10% fetal calf serum,
2 mM GlutaMAX, 16 non-essential amino acids, 44 mM
NaHCO3, 1% Pen/Strep) overlying 0.6% bottom agar in culture
medium. Standard culture medium was added to the cells and
culture proceeded for 4 weeks. Colonies greater than 50 mm were
counted.
Doxorubicin assay
For each assay, 56105 cells were plated on a 10 cm culture dish
and treated with 1 mg/ml doxorubicin-hydrochloride for 24 h.
Cells were then cultured under standard conditions with regular
exchange of medium. After 14 days, colony growth was visualized
by staining with 0.5% crystal violet in 20% methanol.
Supporting Information
Figure S1 Representative primary screening of trans-
fected cell clones. The upper panel shows PCR detection of a
diagnostic 3.31 kb fragment indicating targeted insertion of the
LSL cassette in a series of P53BSR transfected cell clones including
bs29 and bs33 (underlined) that were later used for nuclear
transfer. A plasmid that partially mimicked the structure of the
targeted TP53 locus was diluted in porcine genomic DNA and
used as a positive control, as indicated (+ve). The lower panel
shows amplification of a 3.16 kb fragment from wild-type TP53
from the same cell clones. Size markers are indicated. The
ethidium bromide fluorogram is shown in negative for clarity.
(TIF)
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